scispace - formally typeset
I

Ian C. Lawrance

Researcher at University of Western Australia

Publications -  133
Citations -  14753

Ian C. Lawrance is an academic researcher from University of Western Australia. The author has contributed to research in topics: Inflammatory bowel disease & Ulcerative colitis. The author has an hindex of 34, co-authored 133 publications receiving 13122 citations. Previous affiliations of Ian C. Lawrance include Harry Perkins Institute of Medical Research & St John of God Subiaco Hospital.

Papers
More filters
Journal ArticleDOI

Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease

Luke Jostins, +105 more
- 01 Nov 2012 - 
TL;DR: A meta-analysis of Crohn’s disease and ulcerative colitis genome-wide association scans is undertaken, followed by extensive validation of significant findings, with a combined total of more than 75,000 cases and controls.
Journal ArticleDOI

Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci

Andre Franke, +97 more
- 01 Dec 2010 - 
TL;DR: A meta-analysis of six Crohn's disease genome-wide association studies and a series of in silico analyses highlighted particular genes within these loci implicated functionally interesting candidate genes including SMAD3, ERAP2, IL10, IL2RA, TYK2, FUT2, DNMT3A, DENND1B, BACH2 and TAGAP.
Journal ArticleDOI

Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.

Carl A. Anderson, +113 more
- 01 Mar 2011 - 
TL;DR: A meta-analysis of six ulcerative colitis genome-wide association study datasets found many candidate genes that provide potentially important insights into disease pathogenesis, including IL1R2, IL8RA-IL8RB, IL7R, IL12B, DAP, PRDM1, JAK2, IRF5, GNA12 and LSP1.
Journal ArticleDOI

Maintenance Therapy with Certolizumab Pegol for Crohn's Disease

TL;DR: Patients with moderate-to-severe Crohn's disease who had a response to induction therapy with 400 mg of certolizumab pegol were more likely to have a maintained response and a remission at 26 weeks with continued certolIZumab Pegol treatment than with a switch to placebo.